The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, the 2020 Academy of Dermatology guidelines for managing psoriasis recommends fibrosis‐4 serologic testing and transient elastography at baseline and annually while on methotrexate therapy in patients with risk factors for hepatotoxicity.196”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [196]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Research works printed but not linked: 207
- Kaushik, 2019, Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents, J Am Acad Dermatol, 80, 27, 10.1016/j.jaad.2018.06.057 · DOI · Paper page
- Kaushik, 2019, Psoriasis: which therapy for which patient: focus on special populations and chronic infections, J Am Acad Dermatol, 80, 43, 10.1016/j.jaad.2018.06.056 · DOI · Paper page
- Menter, 2016, Psoriasis and psoriatic arthritis overview, Am J Manag Care, 22, s216
- Fredriksson, 1978, Severe psoriasis—oral therapy with a new retinoid, Dermatologica, 157, 238, 10.1159/000250839 · DOI · Paper page
- Hawkes, 2017, Psoriasis pathogenesis and the development of novel targeted immune therapies, J Allergy Clin Immunol, 140, 645, 10.1016/j.jaci.2017.07.004 · DOI · Paper page
- Heidenreich, 2009, Angiogenesis drives psoriasis pathogenesis, Int J Exp Pathol, 90, 232, 10.1111/j.1365-2613.2009.00669.x · DOI · Paper page
- Lowes, 2014, Immunology of psoriasis, Annu Rev Immunol, 32, 227, 10.1146/annurev-immunol-032713-120225 · DOI · Paper page
- Matthews, 1977, Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate, Science, 197, 452, 10.1126/science.17920 · DOI · Paper page
- Whittle, 2004, Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review, Rheumatology (Oxford), 43, 267, 10.1093/rheumatology/keh088 · DOI · Paper page
- Chan, 2002, Molecular action of methotrexate in inflammatory diseases, Arthritis Res, 4, 266, 10.1186/ar419 · DOI
- Montesinos, 2003, Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68, Arthritis Rheum, 48, 240, 10.1002/art.10712 · DOI · Paper page
- Morgan, 2004, The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis, Arthritis Rheum, 50, 3104, 10.1002/art.20516 · doi:10.1002/art.20516
- Jeffes, 1995, Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate, J Invest Dermatol, 104, 183, 10.1111/1523-1747.ep12612745 · DOI
- Saporito, 2004, Methotrexate and psoriasis in the era of new biologic agents, J Am Acad Dermatol, 50, 301, 10.1016/S0190-9622(03)00803-X · DOI
- Dogra, 2012, Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study, Clin Exp Dermatol, 37, 729, 10.1111/j.1365-2230.2012.04440.x · doi:10.1111/j.1365-2230.2012.04440.x
- Radmanesh, 2011, Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial, Int J Dermatol, 50, 1291, 10.1111/j.1365-4632.2011.04967.x · DOI
- Weinstein, 1971, Methotrexate for psoriasis. A new therapeutic schedule, Arch Dermatol, 103, 33, 10.1001/archderm.1971.04000130035004 · doi:10.1001/archderm.1971.04000130035004
- Menting, 2016, Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation, Acta Derm Venereol, 96, 23, 10.2340/00015555-2081 · doi:10.2340/00015555-2081
- Fallah Arani, 2011, Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial, Br J Dermatol, 164, 855, 10.1111/j.1365-2133.2010.10195.x · doi:10.1111/j.1365-2133.2010.10195.x
- Warren, 2017, An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 528, 10.1016/S0140-6736(16)32127-4 · DOI
- Prey, 2009, Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review, Br J Dermatol, 160, 622, 10.1111/j.1365-2133.2008.08876.x · DOI
- Chladek, 2008, The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis, Eur J Clin Pharmacol, 64, 347, 10.1007/s00228-007-0442-x · doi:10.1007/s00228-007-0442-x
- Cline, 2017, Does daily folic acid supplementation reduce methotrexate efficacy?, Dermatol Online J, 23
- West, 2016, Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials, PLoS One, 11, e0153740, 10.1371/journal.pone.0153740 · doi:10.1371/journal.pone.0153740
- Sbidian, 2017, Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis, Cochrane Database Syst Revs, 12, CD011535
- Barker, 2011, Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1), Br J Dermatol, 165, 1109, 10.1111/j.1365-2133.2011.10615.x · DOI · Paper page
- Saurat, 2008, Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION), Br J Dermatol, 158, 558, 10.1111/j.1365-2133.2007.08315.x · DOI
- Gelfand, 2012, Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting, Arch Dermatol, 148, 487, 10.1001/archdermatol.2012.370 · DOI
- Jabbar-Lopez, 2017, Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis, J Invest Dermatol, 137, 1646, 10.1016/j.jid.2017.04.009 · DOI
- Kingsley, 2012, A randomized placebo-controlled trial of methotrexate in psoriatic arthritis, Rheumatology (Oxford), 51, 1368, 10.1093/rheumatology/kes001 · DOI · Paper page
- Coates, 2016, Methotrexate efficacy in the tight control in psoriatic arthritis study, J Rheumatol, 43, 356, 10.3899/jrheum.150614 · doi:10.3899/jrheum.150614
- Takeshita, 2014, Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting, J Am Acad Dermatol, 71, 1167, 10.1016/j.jaad.2014.08.003 · DOI
- Zachariae, 2008, The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy, Acta Derm Venereol, 88, 495, 10.2340/00015555-0511 · DOI
- Gottlieb, 2012, A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis, Br J Dermatol, 167, 649, 10.1111/j.1365-2133.2012.11015.x · DOI
- Busard, 2014, Combined use of systemic agents for psoriasis: a systematic review, JAMA Dermatol, 150, 1213, 10.1001/jamadermatol.2014.1111 · DOI
- Al-Hamamy, 2014, Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis, Int J Dermatol, 53, 1531, 10.1111/ijd.12444 · doi:10.1111/ijd.12444
- Mahajan, 2010, Methotrexate/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis—a randomized single-blinded placebo-controlled study, J Eur Acad Dermatol Venereol, 24, 595, 10.1111/j.1468-3083.2009.03486.x · DOI
- Soliman, 2015, Combination therapy of methotrexate plus NBUVB phototherapy is more effective than methotrexate monotherapy in the treatment of chronic plaque psoriasis, J Dermatolog Treat, 26, 528, 10.3109/09546634.2015.1034069 · doi:10.3109/09546634.2015.1034069
- Ford, 2018, Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical board of the National Psoriasis Foundation: a systematic review, JAMA Dermatol, 154, 934, 10.1001/jamadermatol.2018.1412 · DOI · Paper page
- Belzunegui, 2001, Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate, Clin Exp Rheumatol, 19, 727
- Brownell, 2007, Folate with methotrexate: big benefit, questionable cost, Br J Dermatol, 157, 213, 10.1111/j.1365-2133.2007.08005.x · doi:10.1111/j.1365-2133.2007.08005.x
- Kremer, 2004, Toward a better understanding of methotrexate, Arthritis Rheum, 50, 1370, 10.1002/art.20278 · DOI · Paper page
- MacDonald, 2005, Noninvasive monitoring for methotrexate hepatotoxicity, Br J Dermatol, 152, 405, 10.1111/j.1365-2133.2005.06605.x · DOI
- Haberman, 2018, Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics, Curr Rheumatol Rep, 20, 76, 10.1007/s11926-018-0785-6 · DOI
- Perez-Chada, 2018, Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative, Arch Dermatol Res, 310, 701, 10.1007/s00403-018-1855-3 · DOI
- Chen, 2017, Methotrexate-induced epidermal necrosis: a case series of 24 patients, J Am Acad Dermatol, 77, 247, 10.1016/j.jaad.2017.02.021 · DOI
- Helliwell, 2008, Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs—comparison of drugs and adverse reactions, J Rheumatol, 35, 472
- Conway, 2015, Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials, BMJ, 350, h1269, 10.1136/bmj.h1269 · DOI
- Menter, 2009, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents, J Am Acad Dermatol, 61, 451, 10.1016/j.jaad.2009.03.027 · DOI · Paper page
- Kalb, 2009, Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference, J Am Acad Dermatol, 60, 824, 10.1016/j.jaad.2008.11.906 · DOI · Paper page
- Kivity, 2014, Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients, Autoimmun Rev, 13, 1109, 10.1016/j.autrev.2014.08.027 · doi:10.1016/j.autrev.2014.08.027
- Boffa, 1996, Methotrexate for psoriasis, Clin Exp Dermatol, 21, 399, 10.1111/j.1365-2230.1996.tb00142.x · doi:10.1111/j.1365-2230.1996.tb00142.x
- Langman, 2001, Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury, J Gastroenterol Hepatol, 16, 1395, 10.1046/j.1440-1746.2001.02644.x · DOI · Paper page
- Rosenberg, 2007, Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment, J Hepatol, 46, 1111, 10.1016/j.jhep.2007.01.024 · DOI · Paper page
- Carneiro, 2008, Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages, J Eur Acad Dermatol Venereol, 22, 25, 10.1111/j.1468-3083.2007.02322.x · doi:10.1111/j.1468-3083.2007.02322.x
- Montaudie, 2011, Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity, J Eur Acad Dermatol Venereol, 25 Suppl 2, 12, 10.1111/j.1468-3083.2011.03991.x · DOI · Paper page
- Menter, 2020, Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients, J Am Acad Dermatol, 82, 161, 10.1016/j.jaad.2019.08.049 · DOI · Paper page
- Hoffmann, 2015, Methotrexate-associated photosensitization [in German], Hautarzt, 66, 459, 10.1007/s00105-014-3569-6 · doi:10.1007/s00105-014-3569-6
- Morris, 1993, Methotrexate and reproduction in men: case report and recommendations, J Am Acad Dermatol, 29, 913, 10.1016/0190-9622(93)70270-4 · DOI
- El-Beheiry, 1979, Methotrexate and fertility in men, Arch Androl, 3, 177, 10.3109/01485017908985067 · doi:10.3109/01485017908985067
- Estop, 1992, Sperm chromosome studies in patients taking low dose methotrexate, Am J Hum Genet, 51, A314
- Sussman, 1980, Psoriasis, methotrexate, and oligospermia, Arch Dermatol, 116, 215, 10.1001/archderm.1980.01640260091025 · doi:10.1001/archderm.1980.01640260091025 · Paper page
- Akhyani, 2010, Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis, J Eur Acad Dermatol Venereol, 24, 1447, 10.1111/j.1468-3083.2010.03667.x · doi:10.1111/j.1468-3083.2010.03667.x
- Barker, 2011, Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic, J Eur Acad Dermatol Venereol, 25, 758, 10.1111/j.1468-3083.2010.03932.x · DOI
- Ho, 2010, Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life, Clin Exp Dermatol, 35, 717, 10.1111/j.1365-2230.2009.03693.x · doi:10.1111/j.1365-2230.2009.03693.x
- Reich, 2010, Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial, J Am Acad Dermatol, 63, 1011, 10.1016/j.jaad.2009.12.029 · doi:10.1016/j.jaad.2009.12.029
- Revicki, 2008, Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis, Br J Dermatol, 158, 549, 10.1111/j.1365-2133.2007.08236.x · DOI · Paper page
- Ogdie, 2018, Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study, J Invest Dermatol, 138, 760, 10.1016/j.jid.2017.10.024 · DOI
- van der Voort, 2016, Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam Study, Acta Derm Venereol, 96, 213, 10.2340/00015555-2161 · DOI
- van der Voort, 2014, Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study, J Am Acad Dermatol, 70, 517, 10.1016/j.jaad.2013.10.044 · DOI · Paper page
- Robert, 2009, A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C, Clin Gastroenterol Hepatol, 7, 335, 10.1016/j.cgh.2008.11.029 · doi:10.1016/j.cgh.2008.11.029
- 1994, Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group, Hepatology, 20, 15
- Regev, 2002, Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection, Am J Gastroenterol, 97, 2614, 10.1111/j.1572-0241.2002.06038.x · doi:10.1111/j.1572-0241.2002.06038.x · Paper page
- Tapper, 2017, Use of liver imaging and biopsy in clinical practice, N Engl J Med, 377, 756, 10.1056/NEJMra1610570 · DOI · Paper page
- Laharie, 2010, Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study, J Hepatol, 53, 1035, 10.1016/j.jhep.2010.04.043 · DOI · Paper page
- Bauer, 2017, Noninvasive testing for nonalcoholic steatohepatitis and hepatic fibrosis in patients with psoriasis receiving long-term methotrexate sodium therapy, JAMA Dermatol, 153, 977, 10.1001/jamadermatol.2017.2083 · DOI
- Maybury, 2014, Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis, Br J Dermatol, 170, 1237, 10.1111/bjd.12905 · DOI
- Rongngern, 2017, Diagnostic performance of transient elastography for detection of methotrexate-induced liver injury using Roenigk classification in Asian patients with psoriasis: a retrospective study, Arch Dermatol Res, 309, 403, 10.1007/s00403-017-1733-4 · DOI
- Bray, 2012, Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy, Br J Dermatol, 166, 1125, 10.1111/j.1365-2133.2011.10657.x · doi:10.1111/j.1365-2133.2011.10657.x
- Tapper, 2015, FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice, Clin Gastroenterol Hepatol, 13, 27, 10.1016/j.cgh.2014.04.039 · DOI · Paper page
- Park, 2017, Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease, Gastroenterology, 152, 598, 10.1053/j.gastro.2016.10.026 · DOI · Paper page
- Hoganson, 2012, Magnetic resonance elastography for liver fibrosis in methotrexate treatment, Open J Rheumatol Autoimmune Dis, 2, 6, 10.4236/ojra.2012.22003 · doi:10.4236/ojra.2012.22003
- Papp, 2015, Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1), J Am Acad Dermatol, 73, 37, 10.1016/j.jaad.2015.03.049 · DOI · Paper page
- Kavanaugh, 2015, Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis, J Rheumatol, 42, 479, 10.3899/jrheum.140647 · DOI
- Danesh, 2015, Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis, Dermatol Online J, 21
- AbuHilal, 2016, Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study, J Cutan Med Surg, 20, 313, 10.1177/1203475416631328 · doi:10.1177/1203475416631328
- Rothstein, 2016, Apremilast and secukinumab combined therapy in a patient with recalcitrant plaque psoriasis, J Drugs Dermatol, 15, 648
- Zerilli, 2015, Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis, P T, 40, 495
- Gottlieb, 2013, Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study, J Drugs Dermatol, 12, 888
- Nast, 2015, Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis, J Invest Dermatol, 135, 2641, 10.1038/jid.2015.206 · DOI
- Papp, 2012, Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial, Lancet, 380, 738, 10.1016/S0140-6736(12)60642-4 · DOI · Paper page
- Paul, 2015, Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2), Br J Dermatol, 173, 1387, 10.1111/bjd.14164 · DOI · Paper page
- Strand, 2013, Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study, Health Qual Life Outcomes, 11, 82, 10.1186/1477-7525-11-82 · DOI
- Mueller, 1979, Cyclosporin A for psoriasis, N Engl J Med, 301, 555, 10.1056/NEJM197909063011015 · DOI · Paper page
- Gottlieb, 1992, Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation, J Invest Dermatol, 98, 302, 10.1111/1523-1747.ep12499782 · DOI
- Prens, 1995, Effects of cyclosporine on cytokines and cytokine receptors in psoriasis, J Am Acad Dermatol, 33, 947, 10.1016/0190-9622(95)90285-6 · doi:10.1016/0190-9622(95)90285-6
- Faerber, 2001, Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients, Am J Clin Dermatol, 2, 41, 10.2165/00128071-200102010-00007 · doi:10.2165/00128071-200102010-00007
- Amor, 2010, The use of cyclosporine in dermatology: part I, J Am Acad Dermatol, 63, 925, 10.1016/j.jaad.2010.02.063 · doi:10.1016/j.jaad.2010.02.063
- Christophers, 1992, Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study, J Am Acad Dermatol, 26, 86, 10.1016/0190-9622(92)70012-5 · doi:10.1016/0190-9622(92)70012-5
- Griffiths, 2004, Ciclosporin in psoriasis clinical practice: an international consensus statement, Br J Dermatol, 150, 11, 10.1111/j.0366-077X.2004.05949.x · DOI
- Shintani, 2011, Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis, J Dermatol, 38, 966, 10.1111/j.1346-8138.2011.01228.x · doi:10.1111/j.1346-8138.2011.01228.x
- Gisondi, 2008, Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial, Am J Clin Nutr, 88, 1242, 10.3945/ajcn.2008.26427 · DOI · Paper page
- Berth-Jones, 1997, Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study, Br J Dermatol, 136, 527
- Ellis, 1991, Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial, N Engl J Med, 324, 277, 10.1056/NEJM199101313240501 · DOI · Paper page
- Ho, 1999, Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group, Br J Dermatol, 141, 283, 10.1046/j.1365-2133.1999.02977.x · doi:10.1046/j.1365-2133.1999.02977.x
- Ho, 2001, Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study, J Am Acad Dermatol, 44, 643, 10.1067/mjd.2001.112400 · doi:10.1067/mjd.2001.112400
- Nast, 2007, German evidence-based guidelines for the treatment of psoriasis vulgaris (short version), Arch Dermatol Res, 299, 111, 10.1007/s00403-007-0744-y · DOI
- Maza, 2011, Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis, J Eur Acad Dermatol Venerol, 25 Suppl 2, 19, 10.1111/j.1468-3083.2011.03992.x · DOI
- Ryan, 2010, The use of cyclosporine in dermatology: part II, J Am Acad Dermatol, 63, 949, 10.1016/j.jaad.2010.02.062 · DOI · Paper page
- Mrowietz, 1995, Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study, J Am Acad Dermatol, 33, 470, 10.1016/0190-9622(95)91393-9 · doi:10.1016/0190-9622(95)91393-9
- Shupack, 1997, Cyclosporine as maintenance therapy in patients with severe psoriasis, J Am Acad Dermatol, 36, 423, 10.1016/S0190-9622(97)80219-8 · doi:10.1016/s0190-9622(97)80219-8
- Lebwohl, 2001, Treatment of psoriasis. Part 2. Systemic therapies, J Am Acad Dermatol, 45, 649, 10.1067/mjd.2001.117047 · DOI · Paper page
- Naldi, 2010, Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies, Clin Dermatol, 28, 88, 10.1016/j.clindermatol.2009.03.003 · DOI
- van de Kerkhof, 2001, Therapeutic strategies: rotational therapy and combinations, Clin Exp Dermatol, 26, 356, 10.1046/j.1365-2230.2001.00829.x · DOI
- Calzavara-Pinton, 2005, A comparative non randomized study of narrow-band (NB) (312 +/-2 nm) UVB phototherapy versus sequential therapy with oral administration of low-dose Cyclosporin A and NB-UVB phototherapy in patients with severe psoriasis vulgaris, Eur J Dermatol, 15, 470
- Markham, 2002, Adverse effects with long-term cyclosporin for severe psoriasis, Clin Exp Dermatol, 27, 111, 10.1046/j.1365-2230.2002.00998.x · DOI
- Laburte, 1994, Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis, Br J Dermatol, 130, 366, 10.1111/j.1365-2133.1994.tb02935.x · doi:10.1111/j.1365-2133.1994.tb02935.x
- Soleymani, 2016, Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review, J Drugs Dermatol, 15, 293
- Ramirez-Fort, 2013, Continuous versus intermittent therapy for moderate-to-severe psoriasis, Clin Exp Rheumatol, 31, S63
- Chaidemenos, 2007, Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis, J Eur Acad Dermatol Venerol, 21, 1203, 10.1111/j.1468-3083.2007.02226.x · doi:10.1111/j.1468-3083.2007.02226.x
- Ohtsuki, 2003, Long-term continuous versus intermittent cyclosporin: therapy for psoriasis, J Dermatol, 30, 290, 10.1111/j.1346-8138.2003.tb00390.x · doi:10.1111/j.1346-8138.2003.tb00390.x
- Lowe, 1996, Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure, J Am Acad Dermatol, 35, 710, 10.1016/S0190-9622(96)90726-4 · doi:10.1016/s0190-9622(96)90726-4
- Silverman, 1992, Can maintenance cyclosporine be used in psoriasis without decreasing renal function?, Semin Dermatol, 11, 302
- Berth-Jones, 2005, The use of ciclosporin in psoriasis, J Dermatolog Treat, 16, 258, 10.1080/09546630500423914 · doi:10.1080/09546630500423914
- Salman, 2013, Proliferative and inductive effects of Cyclosporine a on gingival fibroblast of child and adult, Dent Res J (Isfahan), 10, 52
- Lebwohl, 1998, Cyclosporine consensus conference: with emphasis on the treatment of psoriasis, J Am Acad Dermatol, 39, 464, 10.1016/S0190-9622(98)70325-1 · DOI · Paper page
- Blasco Morente, 2015, Pseudotumor cerebri associated with cyclosporine use in severe atopic dermatitis, Pediatr Dermatol, 32, 237, 10.1111/pde.12273 · doi:10.1111/pde.12273
- Costa, 2010, [Pseudotumor cerebri associated with cyclosporin use following renal transplantation], J Bras Nefrol, 32, 136, 10.1590/S0101-28002010000100022 · doi:10.1590/s0101-28002010000100022
- Somech, 2007, Pseudotumor cerebri after allogeneic bone marrow transplant associated with cyclosporine a use for graft-versus-host disease prophylaxis, J Pediatr Hematol Oncol, 29, 66, 10.1097/MPH.0b013e318030ac3b · doi:10.1097/mph.0b013e318030ac3b
- Gonzalez Vicent, 2001, “Pseudotumor cerebri” following allogeneic bone marrow transplantation (BMT), Ann Hematol, 80, 236, 10.1007/s002770000262 · doi:10.1007/s002770000262
- Ghanem, 2005, Pregnancy outcome after renal allograft transplantation: 15 years experience, Eur J Obstet Gynecol Reprod Biol, 121, 178, 10.1016/j.ejogrb.2004.11.035 · doi:10.1016/j.ejogrb.2004.11.035
- Cochat, 2004, Renal outcome of children exposed to cyclosporine in utero, Transpl Proc, 36, 208S, 10.1016/j.transproceed.2004.01.012 · DOI
- Omar, 2001, Rhabdomyolysis and HMG-CoA reductase inhibitors, Ann Pharmacother, 35, 1096, 10.1345/aph.10228 · doi:10.1345/aph.10228 · Paper page
- Paul, 1987, The effect of ethanol on serum cyclosporine A levels in renal transplant recipients, Am J Kidney Dis, 10, 133, 10.1016/S0272-6386(87)80045-8 · doi:10.1016/s0272-6386(87)80045-8
- Colombo, 2010, Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study, Ing J Immunopathol Pharmacol, 23, 1143, 10.1177/039463201002300418 · DOI
- Grekas, 1993, Influenza vaccination on renal transplant patients is safe and serologically effective, Int J Clin Pharmacol Ther Toxicol, 31, 553
- Soesman, 2000, Efficacy of influenza vaccination in adult liver transplant recipients, J Med Virol, 61, 85, 10.1002/(SICI)1096-9071(200005)61:1<85::AID-JMV14>3.0.CO;2-H · doi:10.1002/(sici)1096-9071(200005)61:1<85::aid-jmv14>3.0.co;2-h
- Versluis, 1986, Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine, Transplantation, 42, 376, 10.1097/00007890-198610000-00009 · DOI
- Powles, 1998, Renal function after 10 years’ treatment with cyclosporin for psoriasis, Br J Dermatol, 138, 443, 10.1046/j.1365-2133.1998.02122.x · doi:10.1046/j.1365-2133.1998.02122.x
- Gilbert, 1989, Cyclosporine therapy for psoriasis: serum creatinine measurements are an unreliable predictor of decreased renal function, J Am Acad Dermatol, 21, 470, 10.1016/S0190-9622(89)70209-7 · DOI
- Altomare, 2014, Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference, G Ital Dermatol Venereol, 149, 607
- Ito, 2014, Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy, J Dermatol, 41, 377, 10.1111/1346-8138.12455 · doi:10.1111/1346-8138.12455
- Reich, 2015, Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest, Arch Dermatol Res, 307, 875, 10.1007/s00403-015-1593-8 · doi:10.1007/s00403-015-1593-8
- Vena, 2012, Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study, J Dermatolog Treat, 23, 255, 10.3109/09546634.2011.565017 · doi:10.3109/09546634.2011.565017
- van de Kerkhof, 1998, The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis, Br J Dermatol, 138, 84, 10.1046/j.1365-2133.1998.02030.x · doi:10.1046/j.1365-2133.1998.02030.x
- Geiger, 1988, Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies, Dermatologica, 176, 182, 10.1159/000248701 · DOI
- Goldfarb, 1988, Acitretin improves psoriasis in a dose-dependent fashion, J Am Acad Dermatol, 18, 655, 10.1016/S0190-9622(88)70086-9 · DOI
- Lassus, 1987, Treatment of severe psoriasis with etretin (RO 10-1670), Br J Dermatol, 117, 333, 10.1111/j.1365-2133.1987.tb04140.x · DOI
- Ling, 1999, Acitretin: optimal dosing strategies, J Am Acad Dermatol, 41, S13, 10.1016/S0190-9622(99)70360-9 · DOI
- Lowe, 1988, Systemic retinoid therapy for psoriasis, J Am Acad Dermatol, 19, 186, 10.1016/S0190-9622(88)70163-2 · DOI
- Murray, 1991, A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study, J Am Acad Dermatol, 24, 598, 10.1016/0190-9622(91)70091-F · DOI
- Olsen, 1989, A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis, J Am Acad Dermatol, 21, 681, 10.1016/S0190-9622(89)70236-X · DOI
- Torok, 1989, Acitretin treatment of severe psoriasis, Acta Derm Venereol Suppl (Stockh), 146, 104
- Gollnick, 1988, Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study, J Am Acad Dermatol, 19, 458, 10.1016/S0190-9622(88)70198-X · doi:10.1016/s0190-9622(88)70198-x
- Kragballe, 1989, A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study, Acta Derm Venereol, 69, 35
- Geiger, 2003, Efficacy of acitretin in severe psoriasis, Skin Ther Lett, 8, 1
- Buccheri, 1997, Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection, Arch Dermatol, 133, 711, 10.1001/archderm.1997.03890420043005 · doi:10.1001/archderm.1997.03890420043005
- Ozawa, 1999, Treatments of generalized pustular psoriasis: a multicenter study in Japan, J Dermatol, 26, 141, 10.1111/j.1346-8138.1999.tb03444.x · doi:10.1111/j.1346-8138.1999.tb03444.x
- Wolska, 1983, Etretinate in severe psoriasis. Results of double-blind study and maintenance therapy in pustular psoriasis, J Am Acad Dermatol, 9, 883, 10.1016/S0190-9622(83)70203-3 · doi:10.1016/s0190-9622(83)70203-3
- Sevrain, 2014, Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion, J Eur Acad Dermatol Venerol, 28, 13, 10.1111/jdv.12561 · doi:10.1111/jdv.12561
- Ozdemir, 2008, A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis, Acta Derm Venereol, 88, 589, 10.2340/00015555-0529 · doi:10.2340/00015555-0529
- Yelverton, 2008, Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis, Arch Dermatol, 144, 1224, 10.1001/archderm.144.9.1224 · doi:10.1001/archderm.144.9.1224
- Lebwohl, 2001, Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis, J Am Acad Dermatol, 45, 544, 10.1067/mjd.2001.116347 · DOI
- Lebwohl, 1999, Acitretin in combination with UVB or PUVA, J Am Acad Dermatol, 41, S22, 10.1016/S0190-9622(99)70362-2 · doi:10.1016/s0190-9622(99)70362-2
- Lowe, 1991, Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone, J Am Acad Dermatol, 24, 591, 10.1016/0190-9622(91)70089-K · DOI · Paper page
- Ruzicka, 1990, Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis, Arch Dermatol, 126, 482, 10.1001/archderm.1990.01670280066012 · DOI
- Iest, 1989, Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone, Br J Dermatol, 120, 665, 10.1111/j.1365-2133.1989.tb01354.x · DOI
- Spuls, 2003, Retrospective study of the efficacy of narrowband UVB and acitretin, J Dermatolog Treat, 14, 17, 10.1080/jdt.14.s2.17.20 · doi:10.1080/jdt.14.s2.17.20
- Lauharanta, 1989, A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis, Br J Dermatol, 121, 107, 10.1111/j.1365-2133.1989.tb01406.x · DOI
- Saurat, 1988, Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis, Dermatologica, 177, 218, 10.1159/000248567 · DOI
- Tanew, 1991, Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study, J Am Acad Dermatol, 25, 682, 10.1016/0190-9622(91)70253-X · DOI · Paper page
- Nijsten, 2003, Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study, J Am Acad Dermatol, 49, 644, 10.1067/S0190-9622(03)01587-1 · DOI
- David, 1988, Adverse effects of retinoids, Med Toxicol Adverse Drug Exp, 3, 273
- Koo, 1997, Advances in psoriasis therapy, Adv Dermatol, 12, 47
- Malloy, 2001, A risk factor for atherosclerosis: triglyceride-rich lipoproteins, Adv Intern Med, 47, 111
- Treewittayapoom, 2012, The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study, J Am Acad Dermatol, 66, 807, 10.1016/j.jaad.2011.12.015 · doi:10.1016/j.jaad.2011.12.015
- Roenigk, 1999, Effects of acitretin on the liver, J Am Acad Dermatol, 41, 584, 10.1016/S0190-9622(99)80058-9 · doi:10.1016/s0190-9622(99)80058-9
- van Ditzhuijsen, 1990, Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin), J Hepatol, 11, 185, 10.1016/0168-8278(90)90111-4 · doi:10.1016/0168-8278(90)90111-4
- DiGiovanna, 1995, Osteoporosis is a toxic effect of long-term etretinate therapy, Arch Dermatol, 131, 1263, 10.1001/archderm.1995.01690230041007 · doi:10.1001/archderm.1995.01690230041007
- Vincent, 2005, Acitretin-induced enthesitis in a patient with psoriatic arthritis, Joint Bone Spine, 72, 326, 10.1016/j.jbspin.2004.06.004 · doi:10.1016/j.jbspin.2004.06.004
- Okada, 1994, Bone mineral density of the lumbar spine in psoriatic patients with long term etretinate therapy, J Dermatol, 21, 308, 10.1111/j.1346-8138.1994.tb01744.x · doi:10.1111/j.1346-8138.1994.tb01744.x
- Van Dooren-Greebe, 1996, Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities, Br J Dermatol, 134, 71, 10.1046/j.1365-2133.1996.d01-742.x · doi:10.1046/j.1365-2133.1996.d01-742.x
- Luthi, 2012, Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain, Joint Bone Spine, 79, 314, 10.1016/j.jbspin.2011.11.001 · DOI
- Vahlquist, 1992, Long-term safety of retinoid therapy, J Am Acad Dermatol, 27, S29, 10.1016/S0190-9622(08)80257-5 · doi:10.1016/s0190-9622(08)80257-5
- Elmets, 2019, Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy, J Am Acad Dermatol, 81, 775, 10.1016/j.jaad.2019.04.042 · doi:10.1016/j.jaad.2019.04.042
- Carpentieri, 2016, Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: a single-center, Italian study, J Dermatolog Treat, 27, 399, 10.3109/09546634.2015.1133885 · doi:10.3109/09546634.2015.1133885
- Singh, 2019, Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis, Arthritis Rheumatol, 71, 5, 10.1002/art.40726 · DOI · Paper page
- Vijayakrishnan, 2011, Treating inflammation with the Janus kinase inhibitor CP-690,550, Trends Pharmacol Sci, 32, 25, 10.1016/j.tips.2010.10.004 · DOI
- Papp, 2015, Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials, Br J Dermatol, 173, 949, 10.1111/bjd.14018 · DOI · Paper page
- Papp, 2012, Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study, Br J Dermatol, 167, 668, 10.1111/j.1365-2133.2012.11168.x · DOI · Paper page
- Bachelez, 2015, Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial, Lancet, 386, 552, 10.1016/S0140-6736(14)62113-9 · DOI · Paper page
- Zand, 2013, Tofacitinab in renal transplantation, Transpl Rev (Orlando), 27, 85, 10.1016/j.trre.2013.04.001 · DOI
- Vincenti, 2015, Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients, Am J Transpl, 15, 1644, 10.1111/ajt.13181 · DOI
- Mrowietz, 2006, Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: results of a phase 3 study, J Am Acad Dermatol, 54, AB202
- Arbiser, 2011, Fumarate esters as angiogenesis inhibitors: key to action in psoriasis?, J Invest Dermatol, 131, 1189, 10.1038/jid.2011.45 · DOI
- Meissner, 2012, Dimethyl fumarate-only an anti-psoriatic medication?, J Dtsch Dermatol Ges, 10, 793
- Atwan, 2015, Oral fumaric acid esters for psoriasis, Cochrane Database Syst Rev, CD010497
- Altmeyer, 1994, Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients, J Am Acad Dermatol, 30, 977, 10.1016/S0190-9622(94)70121-0 · DOI · Paper page
- Mrowietz, 2005, Dimethylfumarate for psoriasis: more than a dietary curiosity, Trends Mol Med, 11, 43, 10.1016/j.molmed.2004.11.003 · DOI · Paper page
- Kolbach, 1992, Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment, J Am Acad Dermatol, 27, 769, 10.1016/S0190-9622(08)80228-9 · doi:10.1016/s0190-9622(08)80228-9
200 of 207 shown
Cited by
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Challenges and Future Trends in the Treatment of Psoriasis
Lee, H.-J., & Kim, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713313 · Cited by 315
Frankowski, M., Świerkot, J., Gomułkiewicz, M., Korman, L., Skoczyńska, M., & Starba, A. (2022) · Rheumatology International · doi:10.1007/s00296-021-05059-z · Cited by 11
Metadata
- Authors
- Menter, A., Gelfand, J. M., Connor, C., Armstrong, A. W., Cordoro, K. M., Davis, D. M. R., Elewski, B. E., Gordon, K. B., Gottlieb, A. B., Kaplan, D. H., Kavanaugh, A., Kiselica, M., Kivelevitch, D., Korman, N. J., Kroshinsky, D., Lebwohl, M., Leonardi, C. L., Lichten, J., Lim, H. W., Mehta, N. N., Paller, A. S., Parra, S. L., Pathy, A. L., Prater, E. F., Rahimi, R. S., Rupani, R. N., Siegel, M., Stoff, B., Strober, B. E., Tapper, E. B., Wong, E. B., Wu, J. J., Hariharan, V., & Elmets, C. A.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 82
- Issue
- 6
- Pages
- 1445-1486
- ISSN
- 0190-9622
- Cited by
- 346
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. https://app.cochat.ai/papers/10.1016/j.jaad.2020.02.044
- The paper
- Menter, A., Gelfand, J. M., Connor, C., Armstrong, A. W., Cordoro, K. M., Davis, D. M. R., Elewski, B. E., Gordon, K. B., Gottlieb, A. B., Kaplan, D. H., Kavanaugh, A., Kiselica, M., Kivelevitch, D., Korman, N. J., Kroshinsky, D., Lebwohl, M., Leonardi, C. L., Lichten, J., Lim, H. W., . . . Elmets, C. A. (2020). Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2020.02.044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.